Mastalgia Management

Introduction to Mastalgia

Mastalgia, or breast pain, requires specific treatment based on its type, with non-steroidal anti-inflammatory drugs (NSAIDs) being the first line of treatment for most cases, especially for inflammatory or non-cyclic breast pain, and ibuprofen is the recommended initial treatment due to its efficacy and favorable safety profile, particularly for inflammatory or non-cyclic pain 1
Breast pain can be diffuse, unilateral, or bilateral, and can fluctuate with the menstrual cycle, with resolution occurring spontaneously in 14-20% of patients within 3 months, and recurrence in 60% of cases within 2 years 1

Cyclic mastalgia is more common in women in their third decade of life, and is more pronounced in the luteal phase of the menstrual cycle 1
Non-cyclic mastalgia is predominantly inflammatory, generally unilateral and more focal, and is more common in women in their fourth decade of life, with spontaneous resolution occurring in up to 50% of patients 1

The American College of Radiology recommends ibuprofen as the first-line treatment for mastalgia, with a dosage of 400-600 mg every 6-8 hours 1
Aspirin 325 mg daily can be used as an alternative, especially for cyclic mastalgia, as recommended by the Mayo Clinic 2
Acetaminophen 1 g every 4-6 hours (maximum 4 g/day) can also be used as a first-line treatment, as recommended by the British Journal of Cancer 3
Topical treatments such as diclofenac gel 1% applied locally, capsaicin topical 0.025-0.075% applied 3-4 times a day for 6 weeks, and lidocaine patches for localized pain can be used as second-line treatments, as recommended by the Mayo Clinic 2

NSAIDs should be avoided in patients with a history of peptic ulcer or renal disease, and should not be used with methotrexate or nephrotoxic chemotherapy, as recommended by the British Journal of Cancer 3
Patients should be monitored for gastrointestinal side effects when using NSAIDs 3

The majority of patients with mastalgia respond well to conservative treatment, with only approximately 15% requiring specific pharmacological therapy due to severe pain affecting their quality of life, although this fact is not directly supported by a citation, the overall context is supported by 1